19 results about "Ceftazidime" patented technology

The application discloses a material for preventing tissue adhesion and hemostasis and a preparation method thereof, and relates to the technical field of medical biomaterials.The carboxymethyl cellulose, chitosan and vancomycin / ceftazidime are synergistically matched, so that the three functions of hemostasis, adhesion prevention and antibiosis are integrated;meanwhile, the water absorption and gelation of the carboxymethyl cellulose and the blood coagulation activation of the chitosan can jointly strengthen the hemostasis effect; the tissue barrier function of the chitosan and the gel isolation of the carboxymethyl cellulose can jointly improve the adhesion prevention performance; the broad-spectrum antibiosis of the vancomycin and the ceftazidime can respond to the infection risk in different surgical scenes; the material preparation process is simple, the dosage form can be adjusted according to different surgical scenes, the material has good biocompatibility and can be completely degraded, the problem that the existing medical materials have single function and are difficult to meet the needs of complex surgical wounds is solved, and the material has significant clinical application value.

The invention provides a synthetic method of a tazobactam intermediate debrominated sulfoxide ester. According to the method, 6-APA is taken as an initial raw material, the 6-APA is prepared through a bromination-(esterification-oxidation)-debromination three-step synthesis reaction one-pot method, acid-catalyst-sodium hypochlorite-benzophenone hydrazone combination is used in the esterification-oxidation step to realize the one-pot reaction, and meanwhile, a hazardous chemical substance peracetic acid is removed. In the debromination step, a combination of illumination, a catalyst and ascorbic acid is adopted to replace zinc powder. Compared with the traditional process, the method has the advantages that the production process is simplified, the safety is better, the molar yield is increased by 13% or above, and the method is suitable for industrial production.

The invention discloses application of gentamicin and ceftazidime in enhancing the drug sensitivity of serratia marcescens, and belongs to the field of biological medicine. The serratia marcescens is a strain carrying drug-resistant genes such as OqxB and mdtC, the mass ratio of gentamicin to ceftazidime is (1: 10)-(1: 50), the synergistic effect of gentamicin and ceftazidime is the strongest under the ratio, the sensitivities of serratia marcescens to gentamicin and ceftazidime can be recovered by 12.5 times and 42 times respectively, MBC is synchronously and greatly reduced, and the serratia marcescens has the dual effects of drug sensitivity enhancement and infection treatment; the single dosage is reduced, so that the cost is reduced, and the potential damage of the medicine to a host is reduced while the treatment effect is ensured. The prodigiosin is effective to serratia marcescens carrying various drug-resistant genes such as OqxB, mdtC, AAC (6 ')-Ic, KdpE and CpxA, cost is saved for prevention, control and treatment of serratia marcescens in animal husbandry, and important reference is provided for safe extraction and utilization of prodigiosin and clinical treatment of human serratia marcescens infection.

The invention discloses a tazobactam crude product mother liquor recovery method, which belongs to the technical field of chemical process, and comprises the following steps: S1, pretreatment: adjusting the pH value of the tazobactam crude product mother liquor to 2.5-4.0; s2, adsorption: adsorbing the pretreated crude product mother liquor through an ion exchange resin column at the temperature of 5-20 DEG C; s3, desorption: using absolute ethyl alcohol as a desorption agent, carrying out desorption on the ion exchange resin column after adsorption, and collecting a desorption solution; s4, crystallization: concentrating the desorption solution at the temperature of not more than 35 DEG C, adding a tazobactam seed crystal, cooling to 0-5 DEG C, and growing the crystal for 20-40 minutes; and S4, suction filtration and drying: performing suction filtration on the material after crystal growing to obtain wet powder, and drying the wet powder to constant weight under the conditions that the temperature is 30-35 DEG C and the pressure is lower than-0.080 MPa to obtain a tazobactam product.

The application belongs to the technical field of medicine synthesis, and particularly relates to a preparation method of ceftazidime hydrochloride and intermediates thereof. The application takes D-7-ACA as raw material, D-7-ACA is salted with a sodium bicarbonate aqueous solution, and then reacts with pyridine under the action of a catalyst to obtain a 7-PYCA reaction liquid; the reaction liquid is subjected to a condensation reaction with ceftazidime active ester to obtain ceftazidime tert-butyl ester; the obtained ceftazidime tert-butyl ester is subjected to a deprotection reaction under the condition of formic acid and hydrochloric acid, and finally crystallization is performed to obtain ceftazidime hydrochloride. The method has the advantages of low cost, high yield and purity, simple process, less waste, high production capacity, and good industrialization value.

The invention belongs to the technical field of medicine synthesis, and discloses a synthesis method of ceftazidime, which comprises the following steps: (1) under the action of an acid-binding agent, carrying out condensation reaction on 7-APCA and alpha-(2-aminothiazole-4-yl)-alpha-[(tert-butyloxycarboryl) isopropoxyimino] acetic acid mercaptobenzene isothiazole ester in a solvent to obtain 7-APCA-alpha (2-aminothiazole-4-yl)-alpha-[(tert-butyloxycarboryl) isopropoxyimino] acetic acid mercaptobenzene isothiazole ester; after the reaction is finished, carrying out post-treatment to obtain ceftazidime tert-butyl ester; in the step (1), the acid-binding agent is isooctylamine and an aniline compound in a mass ratio of (1-5): 1; (2) hydrolyzing and crystallizing the ceftazidime tert-butyl ester obtained in the step (1) under an acidic condition to obtain ceftazidime hydrochloride; and (3) further neutralizing and crystallizing the ceftazidime hydrochloride in the step (2) to obtain the ceftazidime. According to the synthesis method, by adopting the composite acid-binding agent, side reactions are reduced, the content of by-products is reduced, and the purity of the product is improved.

The present invention discloses a zinc coordination polymer, a preparation method thereof and an application thereof in detecting ceftazidime. The coordination polymer chemical formula is {[Zn(fipa)(3-bpdb)2} n , where fipa is a completely deprotonated organic bridging ligand 5-(furan-2-yl)isophthalate, 3-bpdb is an auxiliary ligand 1,4-bis(3-pyridyl)-2,3-dichloro-1,3-butadiene, n represents the degree of polymerization, which is a natural number; each four-coordinated metal Zn is at the center of a distorted tetrahedral geometry. 2+ The zinc coordination polymer is linked to two 1,4-bis(3-pyridyl)-2,3-dichloro-1,3-butadiene chains to form a V-shaped structure. This structure is then connected to a long-range, ordered one-dimensional chain structure along the a-axis by a deprotonated 5-(furan-2-yl)isophthalic acid group. Adjacent chains are connected by abundant hydrogen bonds (C−H···O) and π···π stacking interactions to form a three-dimensional supramolecular framework. The zinc coordination polymer can detect ceftazidime in water in a relatively short time, with high sensitivity, strong selectivity, and good thermal and water stability. It has great potential for the detection of ceftazidime antibiotics.

The present invention belongs to the field of pharmaceutical technology and specifically relates to the use of myrtle ketone derivatives in the preparation of antibacterial drugs and the antibacterial drugs themselves. A novel class of myrtle ketone derivatives synthesized in the present invention exhibits inhibitory activity against Gram-positive bacteria, among which compound 27 is the most potent DNA gyrase and Topo IV inhibitor. Biological activity assays demonstrate that compound 27 not only exhibits rapid bactericidal activity against methicillin-resistant Staphylococcus aureus, but also exhibits low toxicity, is less likely to induce bacterial resistance, and exhibits synergistic effects with first-line antibacterial drugs such as ofloxacin, amikacin, cefpiramide, and ceftazidime, making it a potential candidate for a new antibacterial drug.

This invention discloses a method for determining ceftazidime and its formulation polymers, comprising the following steps: 1) preparing a system suitability solution; 2) preparing a reference solution; 3) preparing a test solution for ceftazidime for injection; 4) determination: injecting the system suitability solution, reference solution, and test solution into a liquid chromatograph, respectively, and performing determination using reversed-phase chromatography, wherein the mobile phase of the reversed-phase chromatography contains mobile phase A and mobile phase B, mobile phase A being an aqueous formic acid solution and mobile phase B being methanol. The chromatogram obtained by the method of this invention has a stable baseline, can detect multiple polymeric impurities of ceftazidime, and exhibits good separation of each impurity; the method of this invention has good specificity and system suitability, and its linearity, sensitivity, repeatability, intermediate precision, and robustness are all good; furthermore, the test solution and reference solution of this invention have high stability.

The invention belongs to the technical field of organic synthesis, and relates to an optimization method of a hydrolysis process in a ceftazidime side chain acid active ester synthesis process, which comprises the following steps: adding a ceftazidime side chain acid ethyl ester intermediate into a hydrolysis mother solution prepared from an organic solvent and water, heating, dissolving, adding a catalyst and an impurity inhibitor, continuing heating, and adding alkali liquor for hydrolysis; after the distillation is finished, adding water, stirring, cooling, dissolving by using alkali liquor, adding sodium pyrosulfite, stirring, adding activated carbon, stirring, decoloring, after decoloring, adjusting the acid by using acid liquor, crystallizing, cooling, and carrying out suction filtration to obtain a hydrolysis crude product; adding the hydrolysis crude product into a mixed solvent, pulping and dissolving, controlling the temperature, preserving the heat, refining, cooling, performing suction filtration, and drying to obtain a hydrolysis product finished product. The reaction efficiency and the product purity are remarkably improved, and experimental results show that the product purity of the optimized process can reach 99.5% or above, and the yield can reach 92% or above.

The present invention provides an antimicrobial combination comprising three different antimicrobial agents The first antimicrobial agent is selected from ceftazidime, polymyxin E, polymyxin B, and pharmaceutically acceptable derivatives thereof; the second antimicrobial agent is selected from zidovudine, doxycycline, fosfomycin and pharmaceutically acceptable derivatives thereof; and the third antimicrobial agent is selected from levofloxacin, doxycycline, fosfomycin, meropenem, rifampicin, gentamicin, polymyxin B / E, and pharmaceutically acceptable derivatives thereof; wherein the combination includes at least one of levofloxacin, doxycycline, rifampicin, fosfomycin, or a pharmaceutically acceptable derivative thereof; provided the combination is not (1) polymyxin E / B, zidovudine and rifampicin or (2) ceftazidime, zidovudine and fosfomycin. Also provided is an antimicrobial combination comprising three antimicrobial agents, wherein the first antimicrobial agent is ceftazidime or a pharmaceutically acceptable derivative thereof; the second antimicrobial agent is zidovudine or a pharmaceutically acceptable derivative thereof; and the third antimicrobial agent is polymyxin E or a pharmaceutically acceptable derivative thereof.

The invention discloses a preparation method of a ceftazidime filling shielding gas for injection, which comprises the following steps: S1, a raw material weighing stage: weighing 1.260 g of a ceftazidime pentahydrate / sodium carbonate mixture by using a precise weighing device, and filling a penicillin bottle with the ceftazidime pentahydrate / sodium carbonate mixture; and S2, a gas detection stage: pre-detecting the concentration of the protective gas, namely pure carbon dioxide, filled into the penicillin bottle by using a gas detection device, and communicating with gas filling equipment after a person is detected to meet the standard. According to the preparation method of the ceftazidime filling shielding gas for injection, pure carbon dioxide is adopted as the product filling shielding gas, the price of the gas is low, proportional adjustment of the gas concentration is omitted, so that the production efficiency is improved, the stability of main medicine components is improved by adopting a method of filling the pure carbon dioxide gas for protection, and the production cost is reduced. Furthermore, pure carbon dioxide gas is adopted for protection, so that crystal water can be fully absorbed, the moisture of the product is controlled within a relatively low range, and the stability of the medicine is further improved.

The application discloses a drug-resistant gene PA3514 of pseudomonas aeruginosa and application of the drug-resistant gene PA3514. The nucleotide sequence of the PA3514 gene is shown as SEQ ID NO. 1. The application finds that the drug resistance level of a pseudomonas aeruginosa PAS56 strain to ceftazidime is improved by 8 times after knocking out the PA3514 gene. Therefore, the PA3514 gene is related to the ceftazidime drug resistance of the pseudomonas aeruginosa.

The invention belongs to the technical field of medicine synthesis, and particularly relates to a preparation method of ceftazidime hydrochloride and an intermediate thereof. The preparation method comprises the following steps: by taking D-7-ACA as a raw material, salifying D-7-ACA with a sodium bicarbonate aqueous solution, and then reacting with pyridine under the action of a catalyst to obtain a 7-PYCA reaction solution; carrying out condensation reaction on the reaction liquid and ceftazidime active ester to obtain ceftazidime tert-butyl ester; and performing deprotection reaction on the obtained ceftazidime tert-butyl ester under the conditions of formic acid and hydrochloric acid, and finally crystallizing to obtain the ceftazidime hydrochloride. The method is low in cost, high in yield and purity, simple in process, less in three wastes and high in productivity, and has a very good industrialization value.

The invention relates to a hybridoma cell strain secreting a ceftazidime monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. A hybridoma cell strain capable of accurately detecting low-concentration ceftazidime is separated, specifically, a monoclonal antibody secreted by the hybridoma cell strain has good sensitivity and specificity to the ceftazidime, the IC50 value of the monoclonal antibody to the ceftazidime is 0.40 ng / mL, the IC50 value of the monoclonal antibody to the ceftazidime is 0.40 ng / mL, and the IC50 value of the monoclonal antibody to a structural analogue of the ceftazidime is 0.40 ng / mL. According to the present invention, ceftazidime with low concentration can be accurately detected, such as cefazolin, cefradine, cefalexin, cefquinoline and cefalotin, no cross reaction exists, and the specificity is good, such that the low-concentration ceftazidime can be accurately detected.

The invention relates to a preparation method of a ceftazidime impurity G. The preparation method comprises the following step: in an organic solvent, preparing a compound shown as a formula III from a compound shown as a formula I and a compound shown as a formula II under an alkaline condition. And performing deprotection on the compound in the formula III under an acidic condition to prepare the ceftazidime impurity G (a compound in a formula IV). The preparation method provided by the invention has the advantages of low purification difficulty, high yield and high product purity, and provides a basis for quality research of ceftazidime.

The application relates to the technical field of ceftazidime production, and particularly discloses a purification method for a key intermediate of ceftazidime. The method is characterized in that triethylamine ethanol solution is added in stages, stirring power is adjusted in stages, and short-time ultrasonic treatment is combined, so that the nucleation and growth process of the crystal is precisely controlled; finally, high-purity PYCA products are obtained through pH adjustment, crystal growth, filtration and drying. The method can effectively avoid explosive generation of crystal nuclei and secondary nucleation, so that PYCA crystals with coarse particles, concentrated particle size distribution and regular morphology can be prepared, impurity wrapping and beta-lactam ring degradation are significantly reduced, the purity of the products can reach more than 99.5%, the content of the maximum impurity is less than 0.15%, the filtration and drying efficiency is greatly improved, and the problems of difficult filtration, long drying period and low product purity in the traditional process are solved. The method is simple in process operation, does not need to introduce complex equipment, is suitable for large-scale industrial production, and has a wide industrial application prospect.

This invention discloses a pan-drug-resistant strain of *Pseudomonas aeruginosa* PAS96 and its applications. *Pseudomonas aeruginosa* PAS96 has the accession number GDMCC No: 64767. This bacterium is resistant to levofloxacin, ciprofloxacin, piperacillin, piperacillin / tazobactam, ticarcillin / clavulanic acid, ceftazidime, meropenem, and imipenem. This invention confirmed the resistance of *Pseudomonas aeruginosa* to the aforementioned antibiotics through Kirby-Bauer (K-B) susceptibility testing.

The invention discloses a method for synthesizing tazobactam diphenylmethyl ester as an intermediate product of tazobactam in a micro-channel reactor, which comprises the following steps: (1) respectively pumping a prepared solution 1 and a prepared solution 2 into the micro-channel reactor, and reacting in the micro-channel reactor in sequence; and (2) quenching, extracting, distilling, pulping, growing crystals, carrying out suction filtration and drying the material at the outlet of the microchannel reactor. And the purity is more than 99.5%. The micro-channel reactor is used in the tazobactam preparation process for the first time, the reaction time can be shortened, two phases are efficiently mixed, and the reaction rate is increased. And the whole reactor can realize continuous feeding, is simple in process operation, and has simple synthesis amplification.